(Date:7/23/2008)...ence Call Scheduled Tuesday, August 5, 2008 at 11:...e-FirstCall/ -- Almost Family, Inc.,(Nasdaq: AFAM...sing,services, announced today that it will report..., 2008 on Tuesday, August 5, 2008, before the,mark... will begin at 11:00 a.m. ET on,August 5, 2008 and...
(Date:7/23/2008)...ON, N.J., July 23 /PRNewswire-USNewswire/ -- The N...lity and Patient Safety has,received a planning gr...dation (RWJF) to develop a proposal for improving ...nt will help determine over the next six months wh...ning Forces for Quality initiative,which is focus...
(Date:7/23/2008)..., China, July 23 /Xinhua-PRNewswire-FirstCall/ -- ...letin Board: GTEC) ("Genesis" or,the "Company"), a...public,of China, held a Board of Directors meeting...appointed to serve on the Board of Directors of th...on Committee were formed., Mr. Michael Marks was ...
(Date:7/23/2008)...ERSBURG, Fla., July 23 /PRNewswire/ -- Laura Kolkm...gnized health information exchange,consulting firm...hcare,Information and Management Systems Society (...ing Committee., The HIE Steering Committee, which...ng providers, payers, vendors, consultants and lif...
Breaking Medicine News(10 mins):Health News:Almost Family, Inc. to Report Second Quarter 2008 Financial Results 2Health News:Genesis Pharmaceuticals Announces New Board Member and Forms Committees 2Health News:Genesis Pharmaceuticals Announces New Board Member and Forms Committees 3Health News:Genesis Pharmaceuticals Announces New Board Member and Forms Committees 4Health News:Mosaica Partners' Kolkman to Chair HIMSS Healthcare Information Exchange Steering Committee 2(Date:7/22/2008)...alidated by Columbia University Medical Center Bas...oRNA Technology, The Test Differentiates Squamou...SCLC), Classifying Squamous-Cell Carcinoma of the ...cificity of 90 Percent,This is the First CLIA Appr... as Biomarkers for Accurate Diagnosis of Lu...
(Date:7/22/2008)...ests That Ekkyo,s New Approach of LASH (Laser Assi...r Healing Physiology, MARSEILLES, France, July 22... Technology) a photomedicine company, which develo...r prevention and reduction, announced today,the pu...gery and Medicine*,reporting the results of a pilo...
(Date:7/21/2008).../- The SEAS (Simvastatin and Ezetimib...ffects of intensive,cholesterol lowering with the ...mibe (10 mg daily) in patients with aortic stenosi...age of the aortic valve in,the heart) is a relativ...opulations. Left untreated, it can progress to dea...
(Date:7/21/2008)...profile helps clinicians identify risk in patients...evels and statin therapy, BIRMINGHAM, Ala., July ...from Atherotech, researchers have identified a lin...n. The information could help,physicians trying to...,disease risk-lowering treatments in at-risk patie...
Breaking Medicine Technology:First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 2First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 3First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 4First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 5Ekkyo Describes the First Benefits of Controlled Hyperthermia in Humans in "Lasers in Surgery and Medicine" 2Ekkyo Describes the First Benefits of Controlled Hyperthermia in Humans in "Lasers in Surgery and Medicine" 3Results From the SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) Study 2Results From the SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) Study 3Results From the SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) Study 4VAP Cholesterol Test Helps Reveal Association Between Adiponectin Levels and Atherosclerosis 2VAP Cholesterol Test Helps Reveal Association Between Adiponectin Levels and Atherosclerosis 3Natural Solutions May Issue Illustrates Cocktail Effect of Everyday Toxins 3B Offers Tips to Reduce Toxic Load 18746 1Natural Solutions May Issue Illustrates Cocktail Effect of Everyday Toxins 3B Offers Tips to Reduce Toxic Load 18746 2Human Genome Sciences Appoints John L Lamattina Ph D to Its Board of Directors 18743 1Human Genome Sciences Appoints John L Lamattina Ph D to Its Board of Directors 18743 2Human Genome Sciences Appoints John L Lamattina Ph D to Its Board of Directors 18743 3Human Genome Sciences Appoints John L Lamattina Ph D to Its Board of Directors 18743 4Genta Incorporated Announces First Quarter 2008 Financial Results and Corporate Highlights 5211 1Genta Incorporated Announces First Quarter 2008 Financial Results and Corporate Highlights 5211 2Genta Incorporated Announces First Quarter 2008 Financial Results and Corporate Highlights 5211 3Genta Incorporated Announces First Quarter 2008 Financial Results and Corporate Highlights 5211 4Genta Incorporated Announces First Quarter 2008 Financial Results and Corporate Highlights 5211 5Genta Incorporated Announces First Quarter 2008 Financial Results and Corporate Highlights 5211 6Genta Incorporated Announces First Quarter 2008 Financial Results and Corporate Highlights 5211 7Genta Incorporated Announces First Quarter 2008 Financial Results and Corporate Highlights 5211 8Anacor to Present Clinical and Preclinical Data on Topical Anti Inflammatory Candidates AN2728 and AN2898 at the International Investigative Dermato 5208 1Anacor to Present Clinical and Preclinical Data on Topical Anti Inflammatory Candidates AN2728 and AN2898 at the International Investigative Dermato 5208 2...ass.--(BUSINESS WIRE)--May 7, 2007 - Alnylam,Pharm...erapeutics,company, presented data from its experi...mic Societies, (PAS) Annual Meeting being,held in ...ent of,the company,s clinical development program ...nt of respiratory syncytial virus (RSV),infection....
...ay 07, 2007 /PRNewswire-FirstCall/ - Isotechnika I...s, reviewed by the,Data Monitoring Committee, of t...e 2b de novo kidney transplant trial for the,Compa...nterim analysis is based upon the assessment of th...patients treated with the,low dose (0.4 mg/kg twic...
Other Medicine Technology:Alnylam Reports Results of Human Experimental Infection Model with,Respiratory Syncytial Virus 2Alnylam Reports Results of Human Experimental Infection Model with,Respiratory Syncytial Virus 3Alnylam Reports Results of Human Experimental Infection Model with,Respiratory Syncytial Virus 4Alnylam Reports Results of Human Experimental Infection Model with,Respiratory Syncytial Virus 5Isotechnika Announces Interim Three Month Data from Phase 2b Kidney,Transplant Trial 2Isotechnika Announces Interim Three Month Data from Phase 2b Kidney,Transplant Trial 3Isotechnika Announces Interim Three Month Data from Phase 2b Kidney,Transplant Trial 4Isotechnika Announces Interim Three Month Data from Phase 2b Kidney,Transplant Trial 5